Placebo + IBI362
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Adolescents With Obesity or Overweight With Weight-Related Comorbidities
Conditions
Adolescents With Obesity or Overweight With Weight-Related Comorbidities
Trial Timeline
Dec 29, 2025 → Oct 31, 2028
NCT ID
NCT07255209About Placebo + IBI362
Placebo + IBI362 is a phase 3 stage product being developed by Innovent Biologics for Adolescents With Obesity or Overweight With Weight-Related Comorbidities. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07255209. Target conditions include Adolescents With Obesity or Overweight With Weight-Related Comorbidities.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07255209 | Phase 3 | Recruiting |
| NCT06937749 | Phase 2 | Recruiting |
| NCT05607680 | Phase 3 | Completed |
Competing Products
3 competing products in Adolescents With Obesity or Overweight With Weight-Related Comorbidities
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lorcaserin | Eisai | Phase 1 | 33 |
| IBI362 + IBI362 placebo | Innovent Biologics | Phase 1 | 32 |
| rizatriptan benzoate | Organon | Phase 3 | 72 |